Earlier Anti-Tumor Necrosis Factor Therapy of Crohn’s Disease Correlates with Slower Progression of Bowel Damage
Sign Up to like & getrecommendations! Published in 2019 at "Digestive Diseases and Sciences"
DOI: 10.1007/s10620-018-5434-4
Abstract: IntroductionCrohn’s disease (CD) follows a relapsing and remitting course incurring cumulative bowel damage over time. The question of whether or not the timing of the initiating biologic therapy affects long-term disease progression remains unanswered. Herein,… read more here.
Keywords: progression; index; bowel damage; disease ... See more keywords
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index
Sign Up to like & getrecommendations! Published in 2019 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2019.1686057
Abstract: Abstract Background: The Lémann Index (LI) was recently developed to evaluate the cumulative bowel damage in patients with Crohn’s disease (CD). Aims: To search for a difference between adalimumab and azathioprine to halt the progression… read more here.
Keywords: bowel; bowel damage; progression bowel; azathioprine ... See more keywords